Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001062993-25-016341
Filing Date
2025-10-29
Accepted
2025-10-28 18:25:35
Documents
12
Period of Report
2024-09-25

Document Format Files

Seq Description Document Type Size
1 FORM 6-K form6k.htm 6-K 12439
2 EXHIBIT 99.1 exhibit99-1.htm EX-99.1 13280
3 EXHIBIT 99.2 exhibit99-2.htm EX-99.2 9253
4 EXHIBIT 99.3 exhibit99-3.htm EX-99.3 4106
5 EXHIBIT 99.4 exhibit99-4.htm EX-99.4 8658
6 EXHIBIT 99.5 exhibit99-5.htm EX-99.5 11061
7 EXHIBIT 99.6 exhibit99-6.htm EX-99.6 10138
8 GRAPHIC exhibit99-1xu001.jpg GRAPHIC 9209
9 GRAPHIC exhibit99-2xu001.jpg GRAPHIC 9097
10 GRAPHIC exhibit99-4x1x1.jpg GRAPHIC 3830
11 GRAPHIC exhibit99-5x1x1.jpg GRAPHIC 9183
12 GRAPHIC exhibit99-6x1x1.jpg GRAPHIC 9834
  Complete submission text file 0001062993-25-016341.txt   127610
Mailing Address 55 UNIVERSITY AVENUE, SUITE 1003 TORONTO Ontario, Canada M5J 2H7
Business Address 55 UNIVERSITY AVENUE, SUITE 1003 TORONTO Ontario, Canada M5J 2H7 (416) 854-8884
Quantum Biopharma Ltd. (Filer) CIK: 0001771885 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39152 | Film No.: 251426178
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)